Taxol (T) and mitoxantrone (M) as first line treatment in advanced breast cancer (ABC) patients. A phase II study of the Southern Italy oncology group (GOIM)
Francesco Giotta(Istituto Tumori Bari), Gianluca Colucci, Vittorio Gebbia(Università degli Studi di Enna Kore), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Luigi Manzione, N. Gebbia
Cited by 1
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234